Clinical trials: Diabetes Type 2
Type 2 Diabetes
CHOlesterol Lowering and Residual Risk in Type 2 Diabetes
The purpose of this study is to investigate why individuals with type 2 diabetes are at increased risk for heart disease and stroke.
- Trial name
- CHORD (NCT04369664)
- Testing
- Statin, PCSK9 inhibitor, Ezetimibe 10mg
- Where
- United States
- Volunteers
- 151 people, healthy volunteers welcome
- Sponsor
- NYU Langone Health
Type 2 Diabetes Mellitus
Feasibility of Once/Daily Administered GLP/1 Receptoragonist (Lixisenatide) in Combination With Basal Insulin
Premixed insulin-based therapy is a standard insulin treatment strategy in Austria. The widespread use of premixed insulin is explained by high acceptance by health care professionals and patients due to one single product and…
- Trial name
- LixiBIT (NCT02168491)
- Testing
- Lixisenatide, Insulin glargine
- Where
- Austria
- Volunteers
- 10 people
- Sponsor
- Medical University of Vienna
Diabetes Mellitus, Type 2
A Study To Compare the Effects of Insulin Peglispro and Glargine on Insulin Sensitivity and Meal Time Insulin Requirements in Type 2 Diabetics
This study will look into insulin sensitivity (how the body responds to insulin) and effects of meals on type 2 diabetics comparing insulin peglispro to insulin glargine.
- Trial name
- NCT02197520
- Testing
- Insulin Peglispro, Insulin Glargine, Insulin Lispro
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Eli Lilly and Company
Diabetic Peripheral Neuropathy
Efficacy and Safety of NYX-2925 in Subjects With Neuropathic Pain Associated With Diabetic Peripheral Neuropathy
To evaluate the efficacy of multiple dose levels of NYX-2925 versus placebo in treating the neuropathic pain associated with Diabetic Peripheral Neuropathy.
- Trial name
- DPN (NCT03219320)
- Testing
- NYX-2925
- Where
- 35 sites in United States
- Volunteers
- 301 people
- Sponsor
- Aptinyx
Type 2 Diabetes, Men
PowerUp for Health: A Diabetes Prevention Program for Men
The purpose of this two-year proposal is to: 1. develop and 2. complete a pilot test of an adaptation of the evidence-based National Diabetes Prevention Program (NDPP) tailored to engage men with prediabetes in disadvantaged…
- Trial name
- NCT02555631
- Testing
- lifestyle
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Type 2 Diabetes
Beta-Cell Dysfunction and Insulin Resistance Among Italian Patients With Type 2 Diabetes (MK-0000-113)
The purpose of this study is to evaluate the degree of beta-cell dysfunction among participants with type 2 diabetes and the association between beta-cell dysfunction and demographic, clinical, and treatment variables.
- Trial name
- BETADECLINE (NCT01472341)
- Volunteers
- 507 people
- Sponsor
- Merck Sharp & Dohme LLC
Overweight, Obesity
Research Study of How Well Semaglutide Works in People Living With Overweight or Obesity.
This study will look at the change in body weight from the start to the end of the study. The purpose of the study is to compare the effect on body weight in people taking semaglutide (a new medicine) and people taking "dummy"…
- Conditions
- Overweight, Obesity, Diabetes Mellitus, Type 2
- Trial name
- STEP7 (NCT04251156)
- Testing
- Semaglutide
- Where
- 33 sites in Brazil, China and 2 more
- Volunteers
- 375 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 2
Trial to Assess the Influence of 4 Weeks' Treatment With Linagliptin as Compared to Glimepiride and Placebo on Endothelial Function in Patients With Type 2 Diabetes Using FMD (Flow-Mediated Vasodilation)
The general aim of the present study is to investigate the impact of 4 weeks treatment with linagliptin (5 mg) on endothelial function in patients with type 2 diabetes mellitus.
- Trial name
- NCT01703286
- Testing
- Linagliptin, Glimepiride
- Where
- Germany
- Volunteers
- 42 people
- Sponsor
- Boehringer Ingelheim
Type2 Diabetes
Continuous Glucose Monitors to Regulate Glucose Levels in Type 2 Diabetics
This study allows Type 2 diabetics to receive feedback from a continuous glucose monitor (CGM) as part of an educational program designed to help them better manage their glucose levels.
- Trial name
- CGM_IRB2 (NCT03252964)
- Testing
- Continuous Glucose Monitor (CGM), Activity Tracker, Coaching
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Savvysherpa, Inc.
Pediatric Obesity
Phentermine/Topiramate in Adolescents With Type 2 Diabetes and Obesity
As the prevalence of obesity rises in the U.S., so does the incidence of pediatric type 2 diabetes (T2D), which is associated with more aggressive disease progression than in adults.
- Trial name
- NCT04881799
- Testing
- Phentermine/Topiramate (Qsymia)
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- University of Minnesota
Diabetes Mellitus, Type 2
A Safety and Pharmacokinetic Study of CVX-096 in Type 2 Diabetics
The purpose of this study is to determine safety and tolerability of CVX-096 in adult, type 2 diabetic patients.
- Trial name
- NCT00886821
- Testing
- CVX-096
- Where
- 2 sites in United States
- Volunteers
- 114 people
- Sponsor
- Pfizer
Nonalcoholic Steatohepatitis (NASH)
A Study of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients With Nonalcoholic Steatohepatitis (NASH)
A Study to Assess the Safety and Potential of Oral Insulin to Reduce Liver Fat Content in Type 2 Diabetes Patients with Nonalcoholic Steatohepatitis (NASH)
- Trial name
- NCT04616014
- Testing
- ORMD-0801 QD
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- Oramed, Ltd.
Type 1 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 1 Diabetes
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
- Trial name
- NCT04450407
- Testing
- LY3209590, Insulin Degludec
- Where
- 54 sites in United States, Austria and 3 more
- Volunteers
- 266 people
- Sponsor
- Eli Lilly and Company
NASH - Nonalcoholic Steatohepatitis, Diabetes Mellitus, Type 2
Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus
The study in the T2DM population is intended to confirm the lanifibranor effect versus placebo on glycemic control and assess a positive effect of the combination of lanifibranor with an SGLT2 inhibitor on glycemic control.
- Trial name
- LEGEND (NCT05232071)
- Testing
- Lanifibranor, Empagliflozin
- Where
- 42 sites in United States, Belgium and 3 more
- Volunteers
- 39 people
- Sponsor
- Inventiva Pharma
Type 2 Diabetes, T2D
A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)
The main purpose of this study is to determine the efficacy and safety of insulin efsitora alfa (LY3209590) administered weekly using a fixed dose escalation compared to insulin glargine in adults with type 2 diabetes (T2D) who…
- Trial name
- QWINT-1 (NCT05662332)
- Testing
- Insulin Efsitora Alfa, Insulin Glargine
- Where
- 71 sites in United States, Argentina and 2 more
- Volunteers
- 795 people
- Sponsor
- Eli Lilly and Company
Type 2 Diabetes
Fresh Food Farmacy: A Randomized Controlled Trial
This trial investigates the value created by the highly innovative Fresh Food Farmacy (FFF) program at Geisinger Health. The program provides food-insecure diabetics with healthy food for their entire household: at least two…
- Trial name
- NCT03718832
- Testing
- Fresh Food Farmacy
- Where
- 2 sites in United States
- Volunteers
- 500 people
- Sponsor
- John B Bulger, DO
Type 2 Diabetes Mellitus
A Trial Comparing Two Therapies: Basal Insulin/Glargine, Exenatide and Metformin Therapy (BET) or Basal Insulin/Glargine, Bolus Insulin Lispro and Metformin Therapy (BBT) in Subjects With Type 2 Diabetes
The study will compare two combination therapies: 1) Combined Basal Insulin Glargine (once a day), Exenatide (twice a day), and Metformin Therapy; or 2) Combined Basal Insulin Glargine (once a day), Bolus Insulin Lispro (three…
- Trial name
- NCT00960661
- Testing
- exenatide, insulin lispro, Metformin
- Where
- 95 sites in Argentina, Belgium and 16 more
- Volunteers
- 1,036 people
- Sponsor
- AstraZeneca
Diabetes Mellitus, Type 2
A Study of LY3493269 in Participants With Type 2 Diabetes
The main purpose of this study is to determine the side effects related to LY3493269 in participants with type 2 diabetes. Blood tests will be performed to check concentrations of LY3493269 in the bloodstream.
- Trial name
- NCT04515576
- Testing
- LY3493269, Dulaglutide
- Where
- 3 sites in United States
- Volunteers
- 56 people
- Sponsor
- Eli Lilly and Company
Diabetes Mellitus, Non-Insulin-Dependent
A Study of Sitagliptin in Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy (0431-054)(COMPLETED)
The clinical study determines the safety and efficacy of Sitagliptin (MK0431) in patients with type 2 diabetes mellitus who have inadequate glycemic control on diet/exercise therapy.
- Trial name
- NCT00411554
- Testing
- sitagliptin phosphate, Comparator: voglibose
- Volunteers
- 319 people
- Sponsor
- Merck Sharp & Dohme LLC
Healthy, Obese
Exercise Regulation of Human Adipose Tissue
The purpose of this study is to determine whether exercise training leads to changes in the white adipose tissue that are beneficial to the body's regulation of sugar and body weight.
- Conditions
- Healthy, Obese, Diabetes Mellitus, Type 2
- Trial name
- NCT03133156
- Testing
- Exercise Intervention
- Where
- United States
- Volunteers
- 93 people, healthy volunteers welcome
- Sponsor
- Joslin Diabetes Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.